KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Operating Margin (2020 - 2026)

AbCellera Biologics filings provide 7 years of Operating Margin readings, the most recent being 691.75% for Q1 2026.

  • Quarterly Operating Margin rose 78783.0% to 691.75% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 267.61% through Mar 2026, up 112773.0% year-over-year, with the annual reading at 288.98% for FY2025, 80271.0% up from the prior year.
  • Operating Margin hit 691.75% in Q1 2026 for AbCellera Biologics, down from 63.72% in the prior quarter.
  • Across five years, Operating Margin topped out at 71.06% in Q1 2022 and bottomed at 1479.57% in Q1 2025.
  • Average Operating Margin over 5 years is 633.22%, with a median of 551.48% recorded in 2024.
  • Peak annual rise in Operating Margin hit 137697bps in 2025, while the deepest fall reached -92810bps in 2025.
  • AbCellera Biologics' Operating Margin stood at 175.34% in 2022, then plummeted by -310bps to 719.61% in 2023, then plummeted by -100bps to 1440.69% in 2024, then surged by 96bps to 63.72% in 2025, then tumbled by -986bps to 691.75% in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Operating Margin are 691.75% (Q1 2026), 63.72% (Q4 2025), and 851.79% (Q3 2025).